Skip to Main Content

Author Details

Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
1999
101
37
PMIDPaper TitleJournal TitlePublished Year
35878714A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer.Int J Radiat Oncol Biol Phys2023
37823778Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.Cancer Res Commun2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37440313LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.JCI Insight2023
36264673Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates.Cancer Cytopathol2023
34764492Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data.Nat Biotechnol2022
35909568The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.Front Endocrinol (Lausanne)2022
36212187Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.Prostate Cancer2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
34973338Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.J Biol Chem2022
35082166Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.Mol Cancer Res2022
35195258Understanding Drug Sensitivity and Tackling Resistance in Cancer.Cancer Res2022
33151257A CHIP in the Armor of Cell-Free DNA-Based Predictive Biomarkers for Prostate Cancer.JAMA Oncol2021
33792558The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.Endocr Relat Cancer2021
33785255Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.Eur Urol2021
33586037De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.Med Oncol2021
33662287Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.Lancet Oncol2021
35008431Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).Int J Mol Sci2021
34554200Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.JAMA Oncol2021
34145028BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.Clin Cancer Res2021
34312180RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.Cancer Res2021
33275486Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.J Clin Oncol2021
32424106Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proc Natl Acad Sci U S A2020
34258585Accelerating precision medicine in metastatic prostate cancer.Nat Cancer2020
31745256Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.Prostate Cancer Prostatic Dis2020
33283137Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study.JCO Precis Oncol2020
33303959Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.Sci Rep2020
32624423Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.Urol Oncol2020
32727885Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2020
32616555A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.J Immunother Cancer2020
32694156A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.Clin Cancer Res2020
32403054Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.Neoplasia2020
30557523Reply to A. Dalla Volta et al.J Clin Oncol2019
30224345Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31565603Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.Cureus2019
30988096Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.Clin Cancer Res2019
30804427MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.Prostate Cancer Prostatic Dis2019
30918106Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.Mol Cancer Res2019
31035489Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma.Metabolites2019
30996246BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer.Oncogene2019
30846826Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.Sci Rep2019
30928160Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
30589921Microsatellite Instability as an Emerging Biomarker for Checkpoint Inhibitor Response in Advanced Prostate Cancer.JAMA Oncol2019
29581250LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.Proc Natl Acad Sci U S A2018
30099369DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.J Natl Compr Canc Netw2018
29985747Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.J Clin Oncol2018
29849118Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.Oncogene2018
30033370Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
30761386Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.JCO Precis Oncol2018
  • 1 - 50 of 101

Recommended Authors

Sinja Taavitsainen
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2018
Number of shared co-authors 16
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 22
Alexandra Corella
Fred Hutchinson Cancer Research Center
Career Start Year 2015
Number of shared co-authors 8
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 30
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 32
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 12
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Career Start Year 2013
Number of shared co-authors 37
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 7
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 42
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 39
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 23
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 2007
Number of shared co-authors 33
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 38
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 8
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 9
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 71
Niven Mehra
Radboud university medical center
Career Start Year 2004
Number of shared co-authors 36
Roberta Ferraldeschi
Astex Pharmaceuticals
Career Start Year 2004
Number of shared co-authors 37
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 57
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 33
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 34
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 47
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 29
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 14
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 24
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 9
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 28
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 44
Oliver Sartor
Tulane University School of Medicine
Career Start Year 1983
Number of shared co-authors 67
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 75

Collaborators

Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 43
Eric J Small
University of California san francisco
Co-authored papers 28
Rahul Aggarwal
University of California San Francisco
Co-authored papers 25
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 23
Martin E Gleave
University of British Columbia
Co-authored papers 18
Adam Foye
University of California San Francisco
Co-authored papers 17
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 16
Christopher P Evans
University of California Davis
Co-authored papers 16
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 15
Thomas J George
UF Health Cancer Center
Co-authored papers 14
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 13
Jacob Schwartzman
12286Rutgers - New Jersey Medical School
Co-authored papers 13
David A Quigley
University of California-San Francisco
Co-authored papers 13
Lina Gao
Oregon National Primate Research Center
Co-authored papers 12
George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 11
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 11
Kim N Chi
University of British Columbia
Co-authored papers 10
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 10
Joshua Urrutia
Knight Cancer Institute, Oregon Health & Science University (OHSU)
Co-authored papers 10
Primo N Lara
University of California Davis Comprehensive Cancer Center
Co-authored papers 10
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 10
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 9
Owen N Witte
University of California los angeles
Co-authored papers 9
Paul Lloyd
Bluestar Genomics Inc.
Co-authored papers 9
Daniel J Coleman
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Colm Morrissey
Co-authored papers 8
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 8
Todd M Morgan
University of Michigan ann arbor
Co-authored papers 7
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 7
Alexander W Wyatt
University of British Columbia
Co-authored papers 7
Release 1.2